Regeneron will seek U.S. approval for its COVID-19 antibody cocktail as a preventative treatment after a trial showed it helped reduce the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday.

REGEN-COV, as the combination shot of casirivimab and imdevimab is called, reduced the overall risk of progressing to symptomatic COVID-19 by 31%, and by 76% after the third day. The trial also demonstrated that it shortened symptom duration and markedly lowered viral levels, Regeneron said in a statement.

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

Regeneron has enlisted Switzerland’s Roche and its massive biotech facility in South San Francisco to help make around 2 million doses annually, a substantial amount although only a fraction of what would be needed to cover the people who get the illness, which is currently infecting about 3.5 million people weekly worldwide.

The drug has emergency U.S. approval for mild to moderate COVID-19 patients, and the companies are hoping the latest trial convinces regulators to expand its deployment. European regulators have voiced some support and are letting countries decide if they want to use it.

Read more at NEWSMAX.